Angina pectoris is a heart condition, which causes chest pain due to coronary heart disease. The situation occurs when the supply of blood is not adequate to the heart. This condition causes pressure, fullness, and pain in the center of the chest. One of the most common causes is the narrowing of coronary arteries, resulting in less supply of blood and oxygen to the heart muscles. The condition is not a heart attack but increases the risk of heart attack for the future. Angina pectoris can be treated by using medication, Angioplasty and vascular stenting, and Coronary artery bypass graft surgery.
MARKET DYNAMICS
The angina pectoris drugs market is anticipated to grow in the forecast period. Increasing lifestyle diseases such as diabetes high cholesterol, cancer, among other chronic diseases, are significant factors resulting in associated cardiovascular diseases worldwide. For instance, 17.9 million people die every year due to CVDs, accounting for 31% of worldwide deaths, the WHO. Moreover, increasing cases of heart diseases are also increasing the chances of angina pectoris. In the U.S., approximately 647,000 Americans die from heart diseases every year, the CDC. Moreover, increasing drug approvals are propelling the growth of the market. For instance, recently, in 2019, Glenmark Pharmaceuticals received approval from the FDA for Ranolazine. It is a generic version of Gilead Sciences.
MARKET SCOPE
The "Global Angina Pectoris Drugs Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of angina pectoris drugs market with detailed market segmentation by therapeutic class and geography. The global angina pectoris drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading angina pectoris drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global angina pectoris drugs market is segmented on the basis of therapeutic class. Based on therapeutic class, the market is segmented as beta blockers, calcium channel blockers, nitrates, angiotensin-converting enzyme inhibitors (ACE Inhibitors), anti-platelets and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global angina pectoris drugs market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The angina pectoris drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting angina pectoris drugs market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the angina pectoris drugs market in these regions.
MARKET PLAYERS
The report covers key developments in the angina pectoris drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from angina pectoris drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for angina pectoris drugs market in the global market. Below mentioned is the list of few companies engaged in the angina pectoris drugs market.
The report also includes the profiles of key angina pectoris drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Sanofi
- Pfizer
- Otsuka Pharmaceutical Co., Ltd.
- Novartis AG
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- Amgen Inc.
- Eli Lilly and Company
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.